Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families

Authors: M Schwab, L Savelyeva, A Claas, H An, S Brouwers

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

Germ line mutations of BRCA2 are predicted to account for the majority of families with both male and female breast cancer. However, there is circumstantial evidence that the cancer risk conferred by BRCA2 mutation may be modified by other genetic or environmental factors. By employing a combination of classical G-banding and fluorescence in situ hybridization analyses we have identified chromosomal alterations on 9p23-24 in peripheral lymphocytes of independent BRCA2 breast cancer patients. Tandem duplication and amplification with inversion are constitutional rearrangements in four male breast cancer patients from two high-risk families. Interstitial deletion of the same region was found in four male and one female patients from an independent family. The biological significance of the coexistence of BRCA2 mutation and 9p23-24 abnormalities in breast cancer families may be complex. Possible explanations include (1) the BRCA2 mutation is related to the 9p-rearrangement, or (2) the 9p rearrangement is elicited by another as yet unknown factor, and chromosomal changes on 9p could be related to modifying cancer risk. …
Metadata
Title
Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families
Authors
M Schwab
L Savelyeva
A Claas
H An
S Brouwers
Publication date
01-03-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr100

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine